ANXA5 and acute myeloid leukemia: To assess the effect of LY2603618 treatment on cell death, first we treated five AML cell lines (CTS, MOLM-13, MV4-11, THP-1, and U937) and one primary AML patient sample (AML #31) with variable concentrations of LY2603618 for 24 h and then subjected them to Annexin V/propidium iodide (PI) staining, and flow cytometry analyses.